1,2,4-triazine has been researched along with Alzheimer Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badri, R; Edraki, N; Firuzi, O; Iraji, A; Khoshneviszadeh, M; Yazdani, M | 1 |
| He, J; Liu, S; Shang, R; Shi, L; Wan, DC; Zhou, R | 1 |
| Dadashpour, S; Emami, S; Irannejad, H; Ozadali, K; Tuylu Kucukkilinc, T; Unsal Tan, O | 1 |
3 other study(ies) available for 1,2,4-triazine and Alzheimer Disease
| Article | Year |
|---|---|
Multi-target inhibitors against Alzheimer disease derived from 3-hydrazinyl 1,2,4-triazine scaffold containing pendant phenoxy methyl-1,2,3-triazole: Design, synthesis and biological evaluation.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Apoptosis; Binding Sites; Drug Design; Humans; Metals; Molecular Docking Simulation; Neuroprotective Agents; PC12 Cells; Rats; Structure-Activity Relationship; Triazines | 2019 |
Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Structure-Activity Relationship; Triazines | 2014 |
Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and β-amyloid aggregation inhibitors.
Topics: Acetates; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Cyclooxygenase 2 Inhibitors; Drug Design; Molecular Docking Simulation; Molecular Structure; Permeability; Plaque, Amyloid; Protein Aggregation, Pathological; Protein Stability; Structure-Activity Relationship; Triazines | 2015 |